Abstract:Schizandrin A, a principal component, demonstrates significant hepatoprotective, antiviral, and anti-inflammatory properties. However, its anti-tumor effects and underlying molecular mechanisms remain poorly understood.We assessed the interaction between Schizandrin A and COX-2/ALOX5 proteins through network pharmacology, molecular docking, and surface plasmon resonance. Conducted bioinformatics analysis, clinical data review, and functional experiments to investigate the significance of schisandrin, COX-2, and ALOX5 in pancreatic cancer (PC) and their interactions. LC/MS metabolomics and RNA sequencing were employed to examine Schizandrin A's impact on COX-2/ALOX5 activation and expression in PC cells. Treatment with Schizandrin A reduced COX-2/ALOX5 activity and inhibited leukotriene and prostaglandin production, affecting NF-kappaB signaling. It significantly inhibited PC cell proliferation while sparing normal tissues and reduced the transformation of normal fibroblasts into cancer-associated fibroblasts. Mutations in binding sites of ALOX5 and COX-2 diminished the affinity for Schizandrin A, blocking its inhibitory effects.Schizandrin A directly inhibits COX-2 and ALOX5, suppressing PC growth and fibroblast transformation, suggesting it as a promising therapeutic agent for pancreatic cancer.

Schizandrin A suppressed pancreatic cancer growth by inhibiting COX-2/ALOX5 shunting.